NF1 mutation

The EAY191-N2/ComboMATCH patient study webpage is now LIVE! Learn more about this treatment trial for people who have hormone receptor-positive metastatic #breastcancer with NF1 mutation. https://t.co/GUp26hJaCs @naborala (@NRGonc)

Our @bcmhouston @BCMCancerCenter #bcsm SPORE project 1 - #comboMATCH @NRGonc trial targeting nonsense, frameshift mutation of NF1 for hormone receptor-positive metastatic breast cancer trial is open for screening!!!! (@naborala)

Congratulations Dr Lindsay @mylovelypinata @IASLC @OncoAlert #NF1 co-mutations #biomarkers #lungcancer #research @TheChristieNHS (@KRASKickers)

Thanks Nitin! Glad to play a small part investigating the resistance mechanisms in these patients. Add CDKN2A to the list of potential acquired resistance mutations (along with KRAS and NF1/2 loss). Thanks to @Skye_Montoya for helping with the beautiful fish plots! #HCLsm #leusm (@TaylorJ_MD)

Super exciting #CancerNeuroscience talk today by @GutmannLab at the #NFconference. Different gremlins Nf1 mutation affects neuronal excitability differently that contributes to the heterogeneity of optic glioma penetrance - recent discoveries by @Corina_Anast 😉 (@YuanPan3)

Exploiting a naturally-occurring germline mutation in patients with #NF1 who do not develop #neurofibromas or #optic gliomas, we employed #hiPSCs and #genetically engineered mice to identify two mechanisms underlying #neuronal activity regulation of #tumor progression. (@GutmannLab)

At #AACR22, @GutmannLab is showing that neurofibromatosis 1 (NF1) mutations drive neuronal activity, which promotes the development of optic #glioma in experimental models. Read more @Nature: https://t.co/TrxxSpCz70 (@NCICancerBio)

Reading about Juvenile Myelomonocytic Leukemia (JMML) today. Some important points - median age Dx 2 yrs (majority <6 yrs) - elevated abs monocyte count - splenomegaly - skin rash - elevated HbF - mutations in Ras-pathway >90% (NF1, PTPN11, NRAS, KRAS) - Allo-SCT 1/2 (@NitinJainMD)

Great work by @EmaFer_90 from @sloan_kettering profiling >700 HER2+ breast cancer: MAPK activating mutations (like NF1) —> anti-HER2 resistance… an attractive therapeutic target… combine HP with MAPKi or use potent ADC? #SABCS21 @BCMCancerCenter @BCMHouston_News (@mfrimawi)

See Advancement in research and therapy of NF1 mutant malignant tumors-https://t.co/RCyhaej2oj T P53 mutations are frequent in malignant NF1 tumors -E.Legius et al https://t.co/8FPIpVte51 NF1 gene in tumor syndromes & Melanoma Maija Kiuru https://t.co/M5PxcJeIYp (@Miultimanota1)

Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia #jmml | @BloodAdvances @ASH_hematology https://t.co/PFmODoWCEh (@dblipka1)

Yes, its very interesting study and really opened the new ways to think (Neuro-oncologists) in howmany more new ways a brain tumor can develop. It's opened our eyes...to close eyes (sometime) of kids with NF1 mutation. Congratulations @GutmannLab @michelle_monje @YuanPan3 (@uchurappaiisc)

Online at @nature: "NF1 mutation drives neuronal activity-dependent initiation of optic glioma" #cancerneuroscience by @michelle_monje and colleagues https://t.co/cerKIn5iZS (@mvicaracal)

KRAS G12C (vs other KRAS mutations) were more likely to have lymphovascular invasion and had a higher #TMB (with more STK11 and NF1 mutations). KRAS also more likely to have high PDL1 expression (37% in KRAS G12C, 35% in KRAS other, 25% in KRAS WT). #LCSM @kRasKickers (@StephenVLiu)

Specific genetic mutations studied in this clinical trial are NF1 mutation for malignant peripheral nerve sheath tumors, NF1, KEAP1/NRF2, or STK11/LKB1 mutation for other solid tumors. (@VivekSubbiah)